Boehringer Ingelheim社、Genedata Selectorを導入：バイオ医薬生産細胞株構築・培養プロセス最適化を支援
Leading pharma company to implement Genedata Selector as its global cell line and genome knowledge management platform
March 8, 2016
Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, industrial biotechnology, agribusiness and life science research, announced today that Boehringer Ingelheim, one of the world’s top pharmaceutical companies, has chosen Genedata Selector™ as its global computational platform for conducting innovative research in genomics-based cell line development and cell culture optimization. Genedata has entered into a long-term strategic collaboration with Boehringer Ingelheim and will also provide bioinformatics consulting services to further optimize R&D operations in Process Sciences.
“Cell line development and cell culture optimization face a new era with the introduction of knowledge-driven genomics based on new technologies such as Next Generation Sequencing (NGS) and omics-based approaches,” said Dr. Harald Bradl, Director, Cell Culture and Process Sciences at Boehringer Ingelheim. “To optimally handle the complex data, we need a centralized genome knowledge management and analysis solution that addresses the interdisciplinary challenges in next-generation biotechnology innovations. Genedata Selector was our obvious choice.”
“We are very excited that Boehringer Ingelheim has selected Genedata Selector for its innovative genomics-based research in cell line development and cell culture optimization,” said Dr. Othmar Pfannes, CEO of Genedata. “Genedata is committed to the continued development of Genedata Selector to make it the solution of choice for researchers to fully leverage the most advanced and innovative technologies used in genome-based research, and for organizations to maximize their return on investment in NGS and omics technologies.”
Knowledge-Based Decision Making and Streamlined Processes to Drive Efficiency
Genedata Selector is an enterprise-level genome knowledge management solution with tailored content for biopharmaceutical applications such as host cell line design, clone validation and the safety assessment of bioproducts. For example, the system provides key information for the identification of the optimized host cell line, the efficient prioritization and validation of engineering targets to improve protein production, or the detection of adventitious agents in the bioproduct. Genedata Selector integrates genomic data from different cell lines and offers standardized and reproducible workflows for the processing and analysis of RNASeq data, e.g. for gene prediction and gene model refinement of proprietary cell lines. Differences between cell lines on the DNA, methylation, protein or pathway level can be elucidated easily using interactive analysis tools included in the system. Engineering targets maximizing functional performance can be efficiently identified and prioritized based on sophisticated regulation and signaling pathway analysis.
On top of providing innovative insights to cell line development and cell culture optimization, Genedata Selector streamlines R&D processes, thereby cutting costs and reducing development times. Genedata Selector’s integrated approach to global knowledge management facilitates collaboration among research groups and sites, with easy access to all data under one umbrella system.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.
For more information please visit www.boehringer-ingelheim.com.
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
To optimally handle the complex data, we need a centralized genome knowledge management and analysis solution that addresses the interdisciplinary challenges in next-generation biotechnology innovations. Genedata Selector was our obvious choice.
Dr. Harald Bradl
Director, Cell Culture and Process Sciences